<body><a name="drugname"></a><table class="topbox" width="100%">
<tr>
<td><span class="topboxgenname">CLEMASTINE FUMARATE</span><br/>(klem'as-teen)<br/><span class="topboxtradename">Tavist, </span><span class="topboxtradename">Tavist-1<br/></span><b>Classifications:</b> <span class="classification">antihistamine (h<sub>1</sub>-receptor antagonist)</span><br/><b>Prototype: </b>Diphenhydramine<br/><b>Pregnancy Category: </b>B<br/></td>
</tr>
</table>
<h1><a name="avail">Availability</a></h1>
<p>1.34 mg, 2.68 mg tablets; 0.67 mg/5 mL syrup</p>
<h1><a name="action">Actions</a></h1>
<p>An antihistamine (H<sub>1</sub>-receptor antagonist) which competes for H<sub>1</sub> receptor sites on effector cells, thus blocking histamine release. Has greater selectivity for preripheral H<sub>1</sub> receptors and, consequently, it produces little sedation. Has prominent antipruritic activity and low incidence of unpleasant
         adverse effects.
      </p>
<h1><a name="therapef">Therapeutic Effects</a></h1>
<p>Effective in controlling various allergic reactions, e.g. nasal congestion, sneezing, itching.</p>
<h1><a name="uses">Uses</a></h1>
<p>Symptomatic relief of allergic rhinitis (sneezing, rhinorrhea, pruritus) and mild uncomplicated allergic skin manifestations
         such as urticaria and angioedema.
      </p>
<h1><a name="contrain">Contraindications</a></h1>
<p>Hypersensitivity to clemastine or to other antihistamines of similar chemical structure; lower respiratory tract symptoms,
         including acute asthma; concomitant <small>MAO INHIBITOR</small> therapy; pregnancy (category B), lactation.
      </p>
<h1><a name="precaution">Cautious Use</a></h1>
<p>History of bronchial asthma, increased intraocular pressure, GI or GU obstruction, hyperthyroidism, cardiovascular disease,
         hypertension, older adults.
      </p>
<h1><a name="rtedsg">Route &amp; Dosage</a></h1>
<table cellpadding="4" cellspacing="0" class="rdbox" width="100%">
<tr>
<td><span class="indicationtitle">Allergic Rhinitis</span><br/><span class="rdage">Adult:</span> <span class="rdroute">PO</span> 1.34 mg b.i.d., may increase up to 8.04 mg/d<br/><span class="rdage">Child:</span> <span class="rdroute">PO</span>
<i>&gt;6 y:</i> 0.67 mg b.i.d., may increase up to 4.02 mg/d; <i> 0.3350.67 mg/kg/d in 2 divided doses (max: 1.34 mg/d)<br/><br/><span class="indicationtitle">Allergic Urticaria</span><br/><span class="rdage">Adult:</span> <span class="rdroute">PO</span> 2.68 mg b.i.d. or t.i.d., may increase up to 8.04 mg/d<br/><span class="rdage">Child:</span> <span class="rdroute">PO</span> 1.34 mg b.i.d., may increase up to 4.02 mg/d<br/></i></td>
</tr>
</table>
<h1><a name="admintn">Administration</a></h1><span class="adminroutetype">Oral</span><br/><ul>
<li>Drug may be administered with food, water, or milk to reduce possibility of gastric irritation.</li>
<li>Older adult patients usually require less than average adult dose.</li>
<li>Store at 15°30° C (59°86° F) unless otherwise directed.</li>
</ul>
<h1><a name="adverse">Adverse Effects (<img src="../images/special/greaterorequal.gif"/>1%)</a></h1><span class="typehead"> Body as a Whole:</span>
<span class="speceff-life">Anaphylaxis</span>, excess perspiration, chills. <span class="typehead">CV:</span> Hypotension, palpitation, tachycardia, extrasystoles. <span class="typehead">GI:</span>
<span class="speceff-common">Dry mouth,</span> epigastric distress, anorexia, nausea, vomiting, diarrhea, constipation. <span class="typehead">Hematologic:</span> Hemolytic anemia, thrombocytopenia, <span class="speceff-life">agranulocytosis</span>. <span class="typehead">CNS:</span> Sedation, <span class="speceff-common">transient drowsiness,</span> dry nose and throat, headache, dizziness, weakness, fatigue, disturbed coordination; confusion, restlessness, nervousness,
      hysteria, convulsions, tremors, irritability, euphoria, insomnia, paresthesias, neuritis. <span class="typehead">Respiratory:</span> Dry nose and throat, thickening of bronchial secretions, tightness of chest, wheezing, nasal stuffiness. <span class="typehead">Skin:</span> Urticaria, rash, photosensitivity. <span class="typehead">Special Senses:</span> Vertigo, tinnitus, acute labyrinthitis, blurred vision, diplopia. <span class="typehead">Urogenital:</span> Difficult urination, urinary retention, early menses. 
      <h1><a name="interactions">Interactions</a></h1><span class="typehead">Drug:</span>
<b>Alcohol</b> and other <span class="classification">cns depressants</span> increase sedation; <span class="classification">mao inhibitors</span> may prolong and intensify anticholinergic effects. 
      <h1><a name="pharmaks">Pharmacokinetics</a></h1><span class="typehead">Absorption:</span> Readily absorbed from GI tract. <span class="typehead">Peak:</span> 57 h. <span class="typehead">Duration:</span> 1012 h. <span class="typehead">Distribution:</span> Distributed into breast milk. <span class="typehead">Metabolism:</span> Metabolized in liver. <span class="typehead">Elimination:</span> Excreted chiefly in urine. 
      <h1><a name="nursing"><span class="implictitle">Nursing Implications</span></a></h1>
<p><span class="adeffecttitle">Assessment &amp; Drug Effects</span></p>
<ul>
<li>Monitor for drowsiness, poor coordination, or dizziness, especially in the older adult or debilitated. Supervision of ambulation
            may be warranted.
         </li>
<li>Assess for symptomatic relief with use of the medication.</li>
<li>Lab tests: Periodic hematological studies with long-term use.</li>
</ul>
<p><span class="eductitle">Patient &amp; Family Education</span></p>
<ul>
<li>Check with physician before taking alcohol or other CNS depressants, since effects may be additive.</li>
<li>Clemastine may cause lethargy and drowsiness; therefore, necessary safety precautions should be taken.</li>
<li>Older adults should make position changes slowly and in stages, particularly from recumbent to upright posture, as dizziness
            and hypotension occur more frequently than in younger patients.
         </li>
<li>Avoid driving and other potentially hazardous activities until response to the drug has been established.</li>
<li>Frequent sips of water or sugarless hard candy to relieve dry mouth.</li>
<li>Do not breast feed while taking this drug.</li>
</ul>
<hr/>
<p><span class="footer">Common adverse effects in <i>italic</i>, life-threatening effects <u>underlined</u>; generic names in <b>bold</b>; classifications in <small>SMALL CAPS</small>; <img border="0" src="../images/maple.gif"/> Canadian drug name; <img border="0" src="../images/pr.gif"/> Prototype drug</span></p>
</body>